eResearch Technology, Inc. (NASDAQ:ERT)

CAPS Rating: 4 out of 5

The Company provides technology and services that enable the pharmaceutical, biotechnology and medical device industries to collect, interpret and distribute cardiac safety and clinical data.

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar RBuskey106 (46.20) Submitted: 3/23/2012 11:26:40 PM : Outperform Start Price: $7.78 ERT Score: -38.62

Strong chart

Recs

0
Member Avatar Calinvestments (96.69) Submitted: 5/13/2011 1:29:32 PM : Outperform Start Price: $6.23 ERT Score: -20.20

This is a small/mid cap high growth stock that should outperform the S&P during the bull market.

Recs

0
Member Avatar mmacioci (28.04) Submitted: 3/2/2011 3:04:26 PM : Underperform Start Price: $6.50 ERT Score: +28.16

Steet Authority Pick undervalued. PE to Eye to short

Recs

0
Member Avatar russiangambit (29.11) Submitted: 2/6/2011 3:25:34 PM : Outperform Start Price: $6.16 ERT Score: -21.54

low price growth

Recs

0
Member Avatar timattox (99.16) Submitted: 11/24/2008 12:17:38 PM : Outperform Start Price: $4.92 ERT Score: -82.75

HiGrowthLoDebt screen

Recs

3
Member Avatar tenmiles (99.66) Submitted: 10/31/2008 10:47:23 AM : Outperform Start Price: $6.18 ERT Score: -84.67

After today's 30% haircut believe ERES is back in the buy zone for patient longs. Strong balance sheet with significant free cash generation; guiding to low teen forward p/e for this grower- buyer at $6.22

Recs

0
Member Avatar heym0n (< 20) Submitted: 6/11/2008 12:12:04 PM : Outperform Start Price: $15.79 ERT Score: -101.99

Exceeded analyst earnings estimates for second straight quarter and price-to-cash-flow ratio well above industry average.

Recs

0
Member Avatar jatava (72.71) Submitted: 5/20/2008 7:31:50 PM : Outperform Start Price: $5.95 ERT Score: -112.25

2.000

Recs

0
Member Avatar Grandeed29 (53.05) Submitted: 5/12/2008 9:20:47 PM : Outperform Start Price: $16.11 ERT Score: -97.15

Highlights for the first quarter of 2008 were:
-- Record quarterly net revenues of $33.7 million, including $3.3 million
of net revenues from Covance Cardiac Safety Services, Inc. (CCSS), a
59.7% increase from the first quarter of 2007.

Recs

0
Member Avatar EMG114 (< 20) Submitted: 5/6/2008 10:57:24 PM : Outperform Start Price: $12.79 ERT Score: -87.07

This company is growing, just look at the trends and reports. Moreover, the pharmaceutical and biotech industries are expanding and could see some considerable earnings in the next few years...

Recs

0
Member Avatar GaTeek (< 20) Submitted: 5/3/2007 6:59:47 PM : Outperform Start Price: $8.70 ERT Score: -47.59

lagging EDC / RX services market comps. Has begun recovery.

Recs

0
Member Avatar CRAZYCAPTAIN (33.09) Submitted: 4/13/2007 10:16:29 AM : Outperform Start Price: $7.75 ERT Score: -42.48

ERES stands to gain as sponsors are resigned to regulatory guidance and the QT interdisciplinary review team has processed 66 TQT protocols for the nine months ended March 31.

Recs

0
Member Avatar Zikar (54.75) Submitted: 3/13/2007 2:54:37 PM : Outperform Start Price: $7.46 ERT Score: -44.78

While their earnings and revenue growth have slowed greatly, they have cash on hand, low debt, and are still posting a profit.

Recs

0
Member Avatar msamet1 (95.74) Submitted: 3/7/2007 10:31:59 AM : Outperform Start Price: $7.41 ERT Score: -43.01

electronic capture of drug studies will increase efficiency of drug development

Recs

0
Member Avatar seekar (< 20) Submitted: 1/28/2007 1:43:40 PM : Outperform Start Price: $6.62 ERT Score: -27.74

I think their business is ready for a turn around. They are the market leader in cardiac studies with 44 of the top 50 pharma companies as customers. Competitirs are other small companies and labs of huge organizations. Expect maybe one more bad quarter before revenues and income increases.

Recs

0
Member Avatar ROSIERMS (< 20) Submitted: 12/14/2006 11:46:53 AM : Outperform Start Price: $6.40 ERT Score: -22.95

will be coming back

Recs

0
Member Avatar tsulistio (< 20) Submitted: 12/1/2006 12:41:30 AM : Underperform Start Price: $6.39 ERT Score: +25.15

Goodrich

Recs

0
Member Avatar rickyroller (< 20) Submitted: 11/29/2006 9:00:24 PM : Outperform Start Price: $6.40 ERT Score: -25.47

this may have hit bottom around $6

Recs

0
Member Avatar SmallTimeBigGuy (31.98) Submitted: 11/28/2006 1:26:02 PM : Outperform Start Price: $6.36 ERT Score: -27.12

Ready for a turnaround. At least short term.

Recs

0
Member Avatar PoorBloke (< 20) Submitted: 9/12/2006 11:15:24 PM : Outperform Start Price: $9.00 ERT Score: -72.24

EResearch conducts studies for the major Pharma firms. They have ben unfairly beaten down due to changes in the FDA's rules, which put several contracts on hold. Now the rules are clearer, their future is brighter.

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners


Advertisement